Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chiron’s Fluvirin Distribution Contracts Under Discussion

This article was originally published in The Pink Sheet Daily

Executive Summary

The company and its vaccine distributors will determine whether contracts for 2004 will be extended for the next flu season given uncertainty over whether Fluvirin will be available. Additional clarity on Fluvirin supply is expected in “early spring.”

You may also be interested in...



Fluvirin FDA Manufacturing Inspections Expected By July

Positive outcome of FDA inspections this summer would be final barrier to re-introducing Fluvirin to the U.S. market. Earlier suspension by U.K. health authorities will not dampen demand for vaccine, Chiron says; the company expects to manufacture 25 mil.-30 mil. doses for 2005/2006 flu season.

Fluvirin FDA Manufacturing Inspections Expected By July

Positive outcome of FDA inspections this summer would be final barrier to re-introducing Fluvirin to the U.S. market. Earlier suspension by U.K. health authorities will not dampen demand for vaccine, Chiron says; the company expects to manufacture 25 mil.-30 mil. doses for 2005/2006 flu season.

GMP Warning Letters With Unusual Language Are Red Flags, Attorney Says

Companies should pay attention to non-boilerplate language inserted at the end of a warning letter, which could signal FDA's intent to pursue more serious enforcement action, Sidley Austin's Bonner says during Drug & Device Dialogue audio conference. A "quiet period" in communications with FDA can precede a seizure, he warns.

Related Content

Topics

UsernamePublicRestriction

Register

ID034708

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel